CIC
IBB icon

Concord Investment Counsel’s iShares Biotechnology ETF IBB Stock Holding History

Concord Investment Counsel’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.22M Buy
27,445
+207
+0.8% +$35.6K 1.42% 24
2026
Q1 		$4.6M Sell
27,238
-282
-1% -$48.2K 1.55% 23
2025
Q4 		$4.64M Sell
27,520
-1,012
-4% -$164K 1.51% 22
2025
Q3 		$4.12M Buy
+28,532
New +$3.89M 1.31% 22
2024
Q1 		$4.52M Buy
+32,975
New +$4.5M 1.63% 19

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Concord Investment Counsel's IBB Position: Q2 2026 in Review

Concord Investment Counsel increased its iShares Biotechnology ETF (IBB) stake by 0.76% in Q2 2026, buying an estimated $35.6K and bringing the position to 27,445 shares worth $5.22M. The position accounts for 1.42% of the portfolio, ranked #24.

Concord Investment Counsel first reported a position in IBB in Q1 2024 and has held it in 5 quarters since. 960 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Concord Investment Counsel held 27,445 shares of iShares Biotechnology ETF worth $5.22M as of Q2 2026.
  • Concord Investment Counsel bought 207 iShares Biotechnology ETF shares in Q2 2026, an estimated $35.6K.
  • iShares Biotechnology ETF made up 1.42% of Concord Investment Counsel's portfolio in Q2 2026, its #24 holding.
  • Concord Investment Counsel first reported a position in iShares Biotechnology ETF in Q1 2024 and has held it in 5 quarters since.
  • 960 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Concord Investment Counsel's 13F filing for Q2 2026, filed 12 Aug 2026.